Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
 | FESTI | 2 | 3 | - | |
 | ALVOTECH | 1 | 5 | 0,00 % | |
| ICELANDAIR GROUP HF | - | 1 | - | |
| ARION BANK | - | - | 0,00 % | ||
| MAREL HF | - | - | - | |
| EIMSKIP | - | - | - | |
| HAGAR | - | - | - | |
| VATRYGGINGAFELAG ISLANDS | - | - | - | |
| BRIM | - | - | - | |
| SJOVA | - | - | - |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Festi hf.: Allocation of share options | 2 | GlobeNewswire (USA) | ||
| Mi | Festi hf.: Presentation of Q1 2024 results | 3 | GlobeNewswire (USA) | ||
| Mi | Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab) | 109 | GlobeNewswire (Europe) | The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid... ► Artikel lesen | |
| Di | Icelandair Group hf.: Financial results Q1 2024 | 29 | GlobeNewswire (Europe) | Revenue increase of 11%, total income USD 259.0 millionRecord passenger revenue USD 199.0 million up by 17% from last year5% decrease in unit costFleet renewal and focus on operational efficiencies... ► Artikel lesen | |
| Di | Festi hf.: Financial results for Q1 2024 | 29 | GlobeNewswire (Europe) | Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted... ► Artikel lesen | |
| Fr | Alvotech moves to bring its Humira biosimilar to US market | 4 | Pharmaceutical Technology | ||
| Fr | Alvotech deal could heighten biosimilar pressure on Humira | 4 | BioPharma Dive | ||
| Fr | Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S. | 29 | Seeking Alpha | ||
| Fr | Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira (adalimumab) | 166 | GlobeNewswire (Europe) | Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
